Cristian Massacesi

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +14

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Alice T. Shaw, Tae Min Kim, Lucio Crinò et al. · The Lancet Oncology · 2017 · 580 citations · Full text

Medicine, Oncology, Pharmacology +12

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata et al. · The Lancet Oncology · 2017 · 539 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

Daniele Santini, Bruno Vincenzi, Giordano Dicuonzo et al. · PubMed · 2003 · 356 citations

Medicine, Oncology, Pharmacology +17

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

Aurélien Marabelle, Robert Hans Ingemar Andtbacka, Kevin J. Harrington et al. · Annals of Oncology · 2018 · 211 citations · Full text

Medicine, Immunology, Oncology +16